A Molecular Urine Assay to Detect Recurrences During Surveillance of High-Risk Non-Muscle Invasive Bladder Cancer.

Background: High-risk non-muscle invasive bladder cancer (HR-NMIBC) patients require long-term surveillance with cystoscopies, cytology and upper tract imaging. Previously, we developed a genomic urine assay for surveillance of HR-NMIBC patients with high sensitivity and anticipatory value.

Objective: We aimed to validate the performance of the assay in an unselected prospectively collected cohort of HR-NMIBC patients under surveillance.

The effect of buoyancy force on natural convection heat transfer of nanofluid flow in triangular cavity with different barriers.

This article aims to investigate the thermophysical properties of viscous nanofluid in the two-dimensional geometry of a triangular cavity containing inverted triangle, square, and rhombus obstacles with different boundary conditions. The boundary conditions of the triangular cavity are investigated in two mechanisms: 1) uniform temperature at the base of the cavity and 2) non-uniform temperature (sinusoidal function) at the base of the cavity. The finite element method was used to solve the governing equations of the viscous nanofluid flow.

Isolated cerebellar metastasis from urothelial carcinoma: A case report of a rare phenomenon.

Introduction: Although urothelial carcinoma (UC) generally is non-invasive, contrastingly in 25% of patients UC metastasizes. Isolated central nervous system (CNS) metastasis from UC without other distant metastases are considered rare. In this report we describe a patient with an isolated and solitary cerebellar metastasis from UC.

Bilateral Adrenal and testicular Tumours; When a Simple Diagnosis Becomes Complicated.

A 78-year-old man with a BMI 28.7, a moon face and a medical history of diabetes mellitus, hypothyroidism, undefined adrenal insufficiency and history of cardiac ablation, had been in urological follow up for both prostate and bladder cancer. PSA remained low after radiation and adjuvant ADT.

Patients and physician satisfaction of Degarelix in androgen deprivation therapy for advanced hormone-dependent prostate cancer in the Netherlands.

Background: To explore the effectiveness and safety of the gonadotropin-releasing hormone antagonist, Degarelix, for the treatment of advanced hormone-dependent prostate cancer (PCa) in a real-world setting.

Methods: In this noninterventional study, patients with advanced hormone-dependent PCa were included. Primary endpoints were progression-free survival (PFS) failure defined as either prostate-specific antigen failure, additional therapy related to PCa, or death.